Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma
Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.
As part of its Between the Lines™ video series, CancerNetwork® spoke with Paul G. Richardson, MD, clinical program leader and director of Clinical Research for the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in Boston, Massachusetts, and Christina Gasparetto, MD, professor of medicine at Duke University Medical School in Durham, North Carolina, about recent updates in the use of proteasome inhibitors for patients with multiple myeloma.
In the video series, Richardson and Gasparetto discussed the following:
- Overview of proteasome inhibitor therapy in multiple myeloma
- Real-world data with proteasome inhibitors
- The phase 3 TOURMALINE-MM1 trial (NCT01564537) of ixazomib therapy in relapsed/refractory multiple myeloma
- Ixazomib plus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma
Be sure to tune in to other videos in the CancerNetwork® Between the Lines™ series.
EP: 1.An Overview of Proteasome Inhibitor Therapy in Multiple Myeloma
EP: 2.Multiple Myeloma: Real-World Data With Proteasome Inhibitors
EP: 3.TOURMALINE-MM1: Ixazomib Therapy in Relapsed/Refractory MM
EP: 4.Proteasome Inhibition in MM: In-Class Transition From Bortezomib to Ixazomib
EP: 5.IRd in Multiple Myeloma: Patient-Reported Adherence and Outcomes
EP: 6.In-Class Transition From Bortezomib to Ixazomib in MM: ASH 2021 Update
EP: 7.Importance of MRD in Treating Patients With Multiple Myeloma
EP: 8.RRMM: Ixazomib Plus Pomalidomide and Dexamethasone
EP: 9.PFS With Ixazomib + Pomalidomide and Dexamethasone in RRMM: Upcoming Trial Data
EP: 10.Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma
EP: 11.Recap: Updates in Proteasome Inhibitors for Managing Multiple Myeloma
![“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F70a5f0fed7009863fe30cf0740cf32014ebaf5be-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.")
![We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fa0c5316b5733cfe8ccceb396476faf0cea2f2e46-320x410.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We found that patients who are [complete remission] MRD-negative, and PET/CT negative year after year for 5 years do not have to be maintained.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
